SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aravive, Inc. (ARAV) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+523.4%).
- Analyst consensus target $0.25 (+523.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ARAV
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.16
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-2.22
Book Value / Share$0.00
Revenue / Share$0.25
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$0.25 (+523.4%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-4.77 |
$0.00 |
$-18.5M |
- |
| 2014 |
$-18.24 |
$0.00 |
$-57.51M |
- |
| 2015 |
$-17.02 |
$0.00 |
$-82.18M |
- |
| 2016 |
$-18.68 |
$0.00 |
$-95.82M |
- |
| 2017 |
$-14.47 |
$40M |
$-84.98M |
-212.4% |
| 2018 |
$-10.64 |
$1.37M |
$-76.33M |
-5567.7% |
| 2019 |
$-1.75 |
$4.75M |
$-20.25M |
-426.1% |
| 2020 |
$-2.17 |
$5.69M |
$-34.24M |
-602.3% |
| 2021 |
$-1.90 |
$7.44M |
$-38.14M |
-512.5% |
| 2022 |
$-2.22 |
$9.14M |
$-80.92M |
-885.6% |
